Stevanato Group S.p.A.

Stevanato Group S.p.A.

14.20
EUR
0.00
(0.00%)
0.51EPS
36.18P/E
5.08BMarket Cap
Mar 11Next Earn
Stevanato Group S.p.A.
GETTEX:87N
(Gettex)

Recent

price

14.20

P/E

ratio

36.18

div

yld

- -

ROIC.AI

2018
2019
2020
2021
2022
2023
2024
2025
TTM
EUR
- -
1.82
2.25
3.34
3.72
4.1
4.07
4.35
4.57
Revenue per Share
- -
0.13
0.27
0.53
0.54
0.55
0.43
0.51
0.51
Basic EPS, GAAP
- -
-0.11
0.2
0.08
-0.53
-1.27
-0.58
0.04
-0.03
Free Cash Flow per Basic Share
- -
0.02
0.03
0.04
0.05
0.05
0.05
0.05
- -
Dividend per Share
0.77
0.88
1.03
3.18
3.76
4.27
5.15
5.44
5.84
Book Value per Share
0.5
0.61
0.76
2.88
3.46
3.96
4.84
5.13
5.5
Tangible Book Value per Share
300
295
295
253
265
265
271
273
273
Basic Weighted Avg Shares
- -
537
662
844
984
1,085
1,104
1,186
1,248
Sales/Revenue/Turnover
- -
11.6
15.57
19.22
19.56
18.49
14.6
16.76
17.66
Operating Margin (%)
- -
46
54
56
65
78
81
89
99
Depreciation Expense
- -
39
79
134
143
146
118
140
140
Net Income, GAAP
- -
29.26
18.37
18.96
23.78
23.14
26.53
26.06
30.74
Effective Tax Rate (%)
- -
7.31
11.86
15.92
14.52
13.42
10.67
11.79
11.25
Profit Margin (%)
151
187
177
527
383
288
403
407
404
Working Capital
262
305
294
202
148
255
317
347
343
LT Debt
231
265
310
842
996
1,133
1,404
1,487
1,594
Total Equity
- -
7.35
12.71
14.68
12.42
10.95
6.92
7.66
7.15
Return on Invested Capital (%)
- -
7.34
12.68
15.73
12.67
10.85
7.31
7.64
7.3
Return on Capital (%)
- -
15.77
27.26
23.31
15.54
13.68
9.29
9.67
9.26
Return on Common Equity (%)

Capital Structure

EUR

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
125
124
126
LT Borrowings
313
312
337
LT Finance Leases
11
7
7
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
273
273
273
Market Capitalization
3,303
4,370
5,080

Working Capital

EUR

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
914
933
959
Cash, Cash Equivalents & STI
113
84
116
Accounts Receivable, Net
278
300
315
Inventories
294
309
302
Total Current Liabilities
560
578
555
Payables & Accruals
290
303
301
ST Debt
125
124
126
Deferred Revenue
54
44
36

Growth Rates

EUR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
46.66%
5.85%
Free Cash Flow
- -
-175.84%
-107%
Net Income, GAAP
- -
15.8%
18.73%
Sales/Revenue/Turnover
- -
12.71%
7.45%
Total Cash Common Dividend
- -
11.07%
1.94%

Quarterly Revenue

EUR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
236
260
278
331
1,104
2025
257
280
303
346
1,186
2026
274
302
326
- -
- -

Quarterly Earnings Per Share

EUR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.07
0.08
0.11
0.18
0.43
2025
0.1
0.11
0.13
0.17
0.51
2026
0.1
0.08
0.15
- -
- -

Quarterly Dividends Per Share

EUR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
0.05
- -
0.05
2025
- -
- -
- -
- -
0.05
2026
- -
- -
- -
- -
- -
Business
Stevanato Group S.p.A. (NYSE: STVN) provides integrated drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries; it operates through two segments, Biopharmaceutical and Diagnostic Solutions, and Engineering, delivering products, processes, and services across the drug life cycle from development to commercialization stages. The company manufactures advanced glass primary packaging under brands such as Ompi, including pre-fillable syringes, vials, cartridges, and ampoules; its EZ-fill pre-sterilized platform; drug delivery systems comprising pen injectors, auto-injectors, wearable injectors, and inhalers; in-vitro diagnostic consumables and medical components; visual inspection systems; assembly, packaging, and glass converting equipment; analytical testing services for container-drug interactions; and contract development and manufacturing for drug delivery devices. Founded in 1949 and headquartered in Piombino Dese, Italy, Stevanato Group maintains a global footprint with facilities across Europe, North America, South America, the Middle East, Africa, and Asia Pacific, including recent expansions such as a new manufacturing hub in Fishers, Indiana, USA, for drug containment and delivery production, and a €200 million financing package in 2025 to bolster capacity in Cisterna di Latina, Italy, and Fishers. In 2025, the company launched the ITC Syringe with Enlarged Inner Cone for enhanced intravenous drug delivery compatibility, expanded drug delivery systems capacity at its German facility to support scalable self-injection technologies, reported third-quarter revenue of €303.2 million reflecting robust growth, and formed the Alliance for RTU with SCHOTT Pharma and Gerresheimer to promote ready-to-use vials and cartridges among contract manufacturers. Stevanato Group, a subsidiary of Stevanato Holding S.R.L., serves pharmaceutical firms, biotech companies, diagnostics providers, and contract manufacturers focused on biologics, injectables, and mRNA therapies.

Company News

  • Stevanato Group to Participate in Upcoming Investor Conferences

  • Stevanato Group to Participate in Upcoming Investor Conferences

  • STVN Investors Have Opportunity to Join Stevanato Group S.p.A. Fraud Investigation with SBS Law

  • STVN Investors Have Opportunity to Join Stevanato Group S.p.A. Fraud Investigation with SBS Law

  • STVN INVESTOR ALERT: Investigation of Stevanato Group S.p.A. Announced by Holzer & Holzer, LLC

  • Lost Money on Stevanato Group S.p.A. Shares? The Law Offices of Frank R.

  • Lost Money on Stevanato Group S.p.A. Stock? Glancy Prongay Wolke & Rotter LLP Investigates Possible Securities Fraud After 28.57% Share Price Drop

  • Did You Lose Money on Stevanato Group S.p.A. Stock? The Law Offices of Howard G.

  • Stevanato Group (STVN) Shareholder Investigation Following Stock Decline – Kehoe Law Firm, P.C.

  • Stevanato Group Q3 Earnings Call Highlights

  • Stevanato Group S.p.A. Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Stevanato Group S.p.A.

  • Stevanato Group S.p.A. (STVN) Q3 2026 Earnings Call Transcript

  • Stevanato Group (STVN) Surpasses Q3 Earnings and Revenue Estimates

  • Stevanato Group Delivers 8% Revenue Growth for the Third Quarter of Fiscal 2026

  • Conestoga Small Cap Composite Q3 2026 Portfolio Activity

  • Stevanato Group and Aptar Pharma Collaborate to Help Accelerate Pre-Filled Syringe System Selection

  • Riverwater Partners Sustainable Value Strategy Q3 2026 Portfolio Update

  • Stevanato Group to Report Third Quarter 2026 Financial Results on November 3, 2026

  • Stevanato Group S.p.A. (STVN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

  • Stevanato Group to Participate in Two Upcoming Investor Conferences